BUY

Sunday Herald Sun - - Finance -

Re­cent weak­ness in the stock price presents an op­por­tu­nity for this com­pany, which is a premium tech­nol­ogy busi­ness op­er­at­ing in the re­tail seg­ment. The re­cent share price weak­ness pro­vides a rare op­por­tu­nity to buy into what is per­haps Aus­tralia’s lead­ing in­ter­na­tional phar­ma­ceu­ti­cal com­pany.

$2.72

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.